Macrophage immunomodulation: An indispensable tool to evaluate the performance of wound dressing biomaterials by Patrícia, Varela et al.
04 August 2020
POLITECNICO DI TORINO
Repository ISTITUZIONALE
Macrophage immunomodulation: An indispensable tool to evaluate the performance of wound dressing biomaterials /
Patrícia, Varela; Sartori, Susanna; Viebahn, Richard; Salber, Jochen; Ciardelli, Gianluca. - In: JOURNAL OF APPLIED
BIOMATERIALS AND FUNCTIONAL BIOMATERIALS. - ISSN 2280-8000. - (2019).
Original
Macrophage immunomodulation: An indispensable tool to evaluate the performance of wound dressing
biomaterials
Publisher:
Published
DOI:
Terms of use:
openAccess
Publisher copyright
(Article begins on next page)
This article is made available under terms and conditions as specified in the  corresponding bibliographic description in
the repository
Availability:
This version is available at: 11583/2727132 since: 2019-03-06T13:34:43Z
Sage
JABFM Journal of Applied Biomaterials & 
Functional 
Materials
https://doi.org/10.1177/2280800019830355
Journal of Applied Biomaterials & 
Functional Materials
January-March: 1 –10
© The Author(s) 2019
Article reuse guidelines: 
sagepub.com/journals-permissions
DOI: 10.1177/2280800019830355
journals.sagepub.com/home/jbf
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  
Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial 
use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and 
Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
Wound healing is a complex process in which different cell 
types (e.g. macrophages) are involved, progression is 
strictly regulated, and different cellular activities overlap.1 
If an atypical progression takes place, a chronic wound 
may result, impacting the patient’s quality of life and the 
economic cost to the healthcare system 2.
Recent research has been focused on understanding the 
factors that influence the healing progress and new discover-
ies elucidating mechanisms of physiologic wound repair have 
been reported. The development of advanced wound dressing 
biomaterials, able to play an active role in wound repair, is 
also a key issue, which is attracting increasing attention.
Therefore, the main objective of this manuscript is to 
review established and recent concepts about wound 
repair, with a focus on chronic wounds, and to underline 
the importance of macrophages in this context, as well as 
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A major burden of the healthcare system resides in providing proper medical treatment for all types of chronic wounds, 
which are usually treated with dressings to induce a faster regeneration. Hence, to reduce healing time and improve 
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the effect of different types of wound dressing biomaterials 
on macrophage function.
Chronic wounds
Chronic wounds: A never-ending nightmare
Non-healing wounds, also known as chronic wounds, of 
diverse etiologies, are a significant health problem world-
wide, being a major cause of morbidity and mortality. 
Owing to the extent of its strong social impact, wounds 
have been described as a “silent epidemic.”2 Concomitant 
with the increase of the obese population, increased dia-
betic patients, and prolongation of life expectancy, the 
number of chronic wound cases is ascending alarmingly. 
Accurate epidemiological analysis concerning chronic 
wounds is scarce; consequently, the determination of the 
precise cost of wound management is affected. 
Nevertheless, there is a body of evidence that the incidence 
of chronic wounds is increasing, becoming an economic 
burden in developed countries.2–4
A wound is characterized by the disturbance of the tis-
sue integrity and structural organization of body cells, with 
or without destroying them.5 If a wound fails to initiate its 
physiologic regeneration after 2–3 weeks and does not 
regain its structural and functional integrity (remaining 
open for 3 months), it is classified as a non-healing 
(chronic) wound.6–8 Examples of chronic wounds are dia-
betic foot ulcers (Figure 1(a)), venous leg ulcers (Figure 
1(b)), and pressure ulcers (Figure 1(c)).9
Disruption of healing process by bacterial 
infection and persistent inflammation
Chronic wounds are associated with an increased risk of 
infection, since long-term cutaneous wounds are more sus-
ceptible, owing to the loss of the protective barrier of intact 
skin. In fact, one of the main causes of impaired wound 
healing is the presence of high bacterial contamination.10 
The progression from contamination through colonization 
to infection on open wounds depends on the bacterial multi-
plication rate, crosstalk between different microorganisms, 
and the initiation of the innate immune response, such as the 
disturbance of a successful recognition and ingestion of 
invading microorganisms, owing to the failure of the opsoni-
zation effect. This effect involves marking pathogens with 
antibodies and factors of the complement system, in order to 
attract phagocytes (e.g. macrophages) to the site of contami-
nation and induce the elimination of the pathogens.11,12 
Figure 2 describes the most common effects induced by the 
progression of bacterial growth in wounds. Starting from a 
contaminated state, in which no major negative signals are 
observed, the system evolves to a severe state (established 
infected wound), in which pathogens proliferate and an 
inflammatory response is clearly activated.
In the past years, there has been increasing evidence that 
bacteria exist in chronic wounds as organized communities, 
in which they are able to cooperate and communicate. 
These colonies are commonly defined as biofilms.10, 14,15 
Biofilms are usually polymicrobial in nature and are sur-
rounded by a self-produced extracellular polysaccharide 
matrix, which contains extracellular enzymes, plasmids, 
and signal molecules for chemical communication (quo-
rum sensing).16 In wound biofilms, blood components may 
Figure 1. Morphology of chronic wounds : (a) colonized diabetic foot ulcer at the heel; (b) infected venous leg ulcer; (c) colonized 
pressure ulcer of the right ischium.
Figure 2. Description of cutaneous wounds by the 
establishment and growth of bacteria.13
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also be enclosed in the matrix.17 Moreover, bacteria show a 
higher tolerance to antibiotics and have a barrier protection 
against the host immune system.11,18
Staphylococcus aureus is the most common bacterial 
species found in chronic wounds, followed by Enterococcus 
faecalis, Pseudomonas aeruginosa, coagulase-negative 
staphylococci, and anaerobic bacteria.19,20
For successful removal of contaminating bacteria, 
inflammation is a crucial part of the normal wound healing 
process. However, when the microbial clearance is incom-
plete, the progression of bacterial growth on wounds 
reaches a critical colonization state and the immunologic 
inflammatory process will be prolonged.1
The combination of the presence of bacteria (especially 
as a biofilm) and persistent inflammatory reaction involves 
the overexpression of pro-inflammatory cytokines (e.g. 
interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), 
chemokines (C-X-C motif ligand 9 (CXCL9), CXCL10, 
and CXCL11) and other signal molecules (e.g. signal 
transducer and activator of transcription 1 and nitric oxide 
synthase 2). This framework is the basis for the continuous 
non-healing status of chronic wounds.1,11
Natural or synthetic antimicrobial wound dressing bio-
materials can play an important role in preventing or 
decreasing the high bacterial contamination and provide a 
chance for the continuation of normal wound healing.21
Wound healing is a highly complex multicellular and 
regulated metabolic process. The normal wound healing 
stages, in timeline order, comprise four overlapping 
phases: hemostasis, inflammation, proliferation, and 
remodeling.22,23 In chronic wounds (Figure 3), bacterial 
critical colonization or infection is present and the inflam-
matory phase is persistent for a long period of time (from 
at least 4 weeks to several months).6 During this period, 
several irregularities are present and, finally, no proper 
shift to the proliferation and remodeling phases occurs.24
Macrophages in wound repair and regeneration
Recruited monocyte-derived macrophages and tissue-resi-
dent macrophages are essential key players in response to 
a tissue injury. After an injury, circulating neutrophils are 
the first to reach the site of damage. This is followed by the 
infiltration of monocytes, which differentiate into mac-
rophages, joining tissue-resident macrophages with the 
mission of restoring integrity.25 Macrophages are mononu-
clear leukocytes, part of the innate immune system, and 
are required for successful skin regeneration.26 In fact, 
macrophages are involved in all phases of wound healing. 
Until recently, this immune cell population was considered 
a “background actor”, but during the last decade scientists’ 
attention exponentially increased, leading them to unveil 
macrophage immunomodulation, which is relevant in 
many diseases.27 Wound healing research has revealed that 
plasticity, flexibility, and heterogeneity of macrophages 
have a crucial participation in obtaining successful cutane-
ous regeneration. Das et al. have compiled several studies 
that clearly prove the participative role of wound mac-
rophages in scavenging, phagocytosis, efferocytosis, anti-
gen presentation, promotion of repair, extracellular 
signaling, and angiogenesis.28 Special attention has been 
given to the capacity of macrophages to remove debris 
from dead and dying cells, as a resolution of inflammation 
and a shift toward regeneration.29
Using a very simplistic nomenclature, macrophages 
are able to polarize into two categories, depending on 
the environmental stimuli: classically activated M1 
pro-inflammatory macrophages, which are involved in 
Figure 3. Abnormalities in the chronic wound environment.
bFGF: basic fibroblast growth factor; PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth factor.
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combating infections, or alternatively activated M2 tis-
sue-healing macrophages, which are connected with tis-
sue remodeling28,30,31 This polarization occurs as a 
continuous spectrum, in which macrophages shift and 
gain different metabolic and phenotypic characteristics 
(Figure 4).
During the inflammatory phase of cutaneous healing, 
M1 macrophages are predominant. These have an 
extremely important role in the phagocytosis of dead or 
dying cells and their components, besides orchestrating 
more macrophages immune cells at the site of injury.32 
M1-like macrophages are known for their high produc-
tion of nitric oxide, an antibacterial oxidative metabo-
lite, and for being efficient antigen-presenting cells. 
Their stimulation is induced, for example, by lipopoly-
saccharides of the outer membrane of Gram-negative 
bacteria or interferon-γ (IFN-γ), and consequently its 
metabolism is activated toward producing high levels of 
pro-inflammatory cytokines, such as IL-1β, IL-6, and 
TNF-α.33 Additionally, this population is characterized 
by the release of reactive oxygen species, mainly derived 
from hydrogen peroxide (H2O2) and superoxide anions 
(O2−).34 Reactive oxygen species have been described as 
chemo-attractants of monocytes to the wound 
location.35
Conversely, M2-like macrophages appear in greater 
quantities during the proliferation and remodeling phases 
of wound healing, during which they express high levels 
of anti-inflammatory cytokines, such as IL-4 and IL-10, 
and the enzyme arginase-1, which is believed to be a main 
contributor to wound healing.26 The classification of 
M2-like macrophages is still controversial and a subject of 
persistent study; hence, many types of subdivision are 
found in the literature, especially depending on specific 
diseases. It is not clear whether these intermediate pheno-
types can be divided in such a strict categorized manner, 
owing to their plasticity through a continuous spectrum. 
However, it seems currently well accepted that M2-like 
macrophages are divided into four different subtypes 
(M2a, M2b, M2c, and M2d) in what concerning the wound 
healing process (Table 1).32,36,37
Briefly, M2a macrophages release platelet-derived 
growth factors and stimulate fibroblasts to proliferate and 
secrete extracellular matrix, an essential factor for angio-
genesis in wound repair.33 M2b macrophages have been 
shown to have an important function in decreasing the 
inflammatory process by synthesizing high levels of the 
anti-inflammatory cytokine IL-10, despite the fact that 
these cells still produce pro-inflammatory cytokines (e.g. 
TNF-α).23,26 M2c macrophages are intervenient in vascu-
lar and matrix renovation, owing to the high production of 
extracellular matrix. Lastly, M2d macrophages are pro-
angiogenic and produce high levels of vascular endothelial 
growth factor.32
Figure 4. Macrophage polarization occurring in a spectrum between M1 and M2 macrophages.
Arg 1: arginase 1; iNOS: inducible nitric oxide synthase.
Table 1. Most common characteristics of M2-like macrophages subtypes.23,32,38–41
M2 subtype Stimulation Membrane receptors Secretion
 Cytokines Chemokines Signals
M2a IL-4, IL-13 CD163, CD206 IL-10, IL-1RA CCL17, CCL18, 
CCL22, CCL24
STAT-3, Arg1, TGF-β
M2b IC, TLR/IL-1R 
ligands
CD86, MHC-II TNF-α, IL-1β, IL-6,
IL-10
CCL1 SOCS3, COX-2
M2c IL-10 CD86, CD163, CD206 IL-10 CCL16, CCL18, 
CXCL13
Arg 1, EGF, TGF-β, 
MMP-9
M2d IL-6 CD14, CD16, CD68 TNF-α, IL-10, IL-12 CXCL10 TGF-β, VEGF
Arg1, arginase; CCL, C-C motif ligand; CCR, C-C chemokine receptor; CD, cluster of differentiation; COX, cyclooxygenase; CXCL, C-X-C motif 
ligand; EGF, epidermal growth factor; IC, immune complex; IGF, insulin-like growth factor; IL, interleukin; IL-1RA, IL-1 receptor antagonist; MHC, 
major histocompatibility complex; MMP: matrix metalloproteinase; SOCS, suppressor of cytokine signaling; STAT, signal transducer and activator of 
transcription; TGF, transforming growth factor; TLR, toll-like receptor; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
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Macrophages: Dysfunction in chronic wounds
Non-healing wounds can be exacerbated because of improp-
erly acting macrophages. In normal wound healing, mac-
rophages induce an initial pro-inflammatory response and 
shift to a pro-repairing action. This inflammatory-to-regen-
erative shift is completely dependent on their capacity to 
perform phagocytosis of dead neutrophils and remaining 
debris.42 In healthy processes, M1 macrophages are partially 
converted to M2b macrophages to overcome inflammation; 
however, M1 macrophages can accumulate in chronic 
wounds, owing to environmental stimuli that do not allow 
the transition.32 As a consequence, a highly inflammatory 
environment is maintained, and wound closure is delayed, 
as proved by the increased levels of IL-1 and TNF- α (pro-
inflammatory cytokines produced by M1-like macrophages) 
in chronic wound fluids.43 Moreover, the fluid also contains 
higher levels of matrix metalloproteinases than those usu-
ally observed during the proliferation and remodeling 
phases, leading to protein and extracellular matrix degrada-
tion, and, as a consequence, impaired tissue regeneration.44 
Dysregulation of M2-like macrophages is also a big con-
cern. Alteration of their typical phenotype and metabolic 
characteristics dictates the level of collagen deposition and 
scar formation.32 As an example, an overexpression of type-
III collagen has been found in hypertrophic scars.45
Wound dressings
The correct selection of wound dressing biomaterials is 
vital for a faster wound recovery of patients with non-heal-
ing cutaneous injuries. Hence, studies must provide infor-
mation about biocompatibility, possible antibacterial 
efficacy, and material properties.46
Such products as bandages and gauzes, of natural or 
synthetic origin, are commonly used to cover an acute 
wound to prevent contamination.47 This type of dressing 
lacks many features for proper wound healing, such as 
maintaining wound hydration and preventing wound con-
tamination. Modern wound dressings, based on polymers, 
can be made bioactive by the incorporation of antibiotics 
(e.g. gentamicin), metals (e.g. silver), or growth factors 
(e.g. fibroblast growth factor 1).48
Unsurprisingly, the diverse surface morphologies and 
incorporated active components will induce an effect on 
the phenotype and metabolism of macrophages. Hence, it 
is extremely important to study the immunomodulatory 
effects of wound dressing biomaterials.
Wound healing biomaterials to the rescue: Are 
biomaterial–macrophage interactions friends or 
foes?
Countless wound dressings are commercially available, 
and a number of new dressings are under development, but 
their mechanisms of action are poorly understood. 
Therefore, there is a great interest in exploring immune 
cell–biomaterial interactions. Owing to the importance of 
the effector functions of macrophages, it has become 
essential to obtain evidence about the polarization of mac-
rophages and immunomodulation in the presence of differ-
ent biomaterials.49 As previously discussed, macrophages 
are dysregulated in non-healing wounds. Furthermore, a 
correlation between prolonged M1 cell populations and 
delayed wound repair has been demonstrated.50 The impor-
tance of a wound dressing biomaterial that is able to stimu-
late the shift from M1 to M2 tissue-healing macrophages, 
or at least to avoid M1 pro-inflammatory phenotype per-
petuation, is thus clearly evident. In the rest of this paper, 
relevant work describing the effect of non-commercially 
and commercially available wound dressing biomaterials 
on the immunomodulation of macrophages (Table 2) will 
be analyzed. To test their response to wound dressings, 
various techniques can be applied to macrophages after 
exposition to the biomaterial influence, such as gene up- or 
downregulation evaluation by polymerase chain reaction, 
determination of expressed membrane markers through 
flow cytometry, secretion of cytokines and other signal 
molecules by enzyme-linked immunosorbent assay, and 
evaluation of posttranslational proteins by proteomics.
Commercially available wound dressings. Alginate dressings 
are widely used in the treatment of exuding wounds and 
may enhance the healing process. Thomas and co-workers 
evaluated the capacity of interaction between alginates 
present in commercially available absorbent wound dress-
ings with macrophages,49 and observed that macrophages 
derived from the human histiocytic lymphoma cell line 
U937 in the presence of a calcium alginate dressing (Sorb-
san) at 1 mg/mL stimulated the production of 302 ± 19 pg/
mL of TNF-α and that the alginate calcium sodium dress-
ing Kaltostat induced the production of 839 ± 36 pg/mL of 
TNF-α. Two other alginate dressings were also tested 
without significant differences. Thomas and co-workers 
concluded that alginate dressings have the potential to 
improve wound healing, owing to the ability to activate 
wound macrophages in producing TNF-α, a pro-inflam-
matory signal.49 This cytokine has been found to be 
secreted by M2b and M2d macrophages but, contradicto-
rily, it has been proved that prolonged expression of TNF-
α contributes to a delayed wound healing, for example, in 
diabetic wounds.51
In a study conducted by Witherel and collaborators,52 
the responses of monocyte-derived macrophages isolated 
from blood (one donor) to four currently applied wound 
dressing biomaterials were analyzed and compared. The 
four wound dressing biomaterials were:
(a) OASIS® Wound Matrix. Extracellular matrix from 
porcine small intestinal mucosa;
6 Journal of Applied Biomaterials & Functional Materials 00(0)
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(b) INTEGRA™ Bilayer Matrix. Dermal layer made of 
porous fiber matrix of cross-linked bovine tendon 
type I collagen and chondroitin-6-sulfate, epider-
mal layer constituted of polysiloxane;
(c) AlloMend® Acellular Dermal Matrix. 
Decellularized matrix composed mainly of colla-
gen and elastin;
(d) PriMatrix® Dermal Repair Scaffold. Decellularized 
fetal bovine dermis rich in type I and II collagen.
The expression of M2a anti-inflammatory markers CCL22 
and TIMP3 in the presence of OASIS® and INTEGRA™ 
was downregulated; this suggests a possible inhibition of 
extracellular matrix secretion and fibrosis, which are key 
phenomena for wound closure. OASIS® was also respon-
sible for the largest increase of expression of M1 genes; 
hence, Witherel and collaborators52 considered this prod-
uct significantly pro-inflammatory. Although INTEGRA™ 
is constituted of collagen I and the anti-inflammatory 
chondroitin-6-sulfate, an opposite effect was observed and 
the reason might be the presence of glutaraldehyde in this 
dressing. OASIS® and INTEGRA™ seem to be a poor 
option for chronic wound cases.
In the case of PriMatrix®, a downregulation of the genes 
CCL22 and TIMP3 was also observed. Moreover, this 
wound dressing caused an overexpression of the pro-
inflammatory cytokine TNF-α and increased the expres-
sion of CD163, associated with M2c, which is a less 
fibrotic phenotype.52 For last, AlloMend® only induced an 
effect of the upregulation of CD163, and it was considered 
the dressing with the lowest influence on macrophage 
response. Overall, this work shows that the dressings have 
a direct effect on macrophage immunomodulation, and 
give us a very important take home message, which is “the 
same wound dressing can have a dual effect promoting the 
polarization to M1- and M2-like macrophages”.
Non-commercially available materials for wound dress-
ings. Composites produced from keratin, cellulose, and 
chitosan have shown bactericidal and anti-inflammatory 
properties.53 For instance, chitosan is well known for its 
highly antimicrobial activity against fungi and bacteria.54 
As a result of these properties, chitosan is used in the pro-
duction of commercial wound dressing products, such as 
Tegasorb® and KytoCel®, alone or in combination with 
synthetic polymers, such as poly(ε-caprolactone) and pol-
yethylene oxide.55,56 Anti-inflammatory properties were 
detected on THP-1 derived macrophages in the presence of 
composites produced from keratin, cellulose, and chi-
tosan53 Herein, the authors of these studies noticed that the 
composites induced an increase in the expression of 
CD11b on macrophages. As a support, it has been proven 
that the depletion of CD11b+ macrophages in a bacterial 
pathogen-induced inflammation model delayed inflamma-
tion resolution and antigen clearance, indicating its impor-
tance for proper wound healing.57
In a study of Merrell and co-workers, curcumin-loaded 
poly(ε-caprolactone) (PCL) nanofibers were evaluated for 
wound healing applications.58 PCL is a synthetic polymer 
utilized in wound dressing biomaterials59; it possesses sev-
eral advantages over other synthetic polymers, including 
stability, low cost, mechanical strength, and biocompati-
bility.60 In combination with the anti-oxidant curcumin, 
these novel nanofibers reduced the anti-inflammatory 
reaction, proven by the low release of IL-6 observed in 
mouse monocyte-derived macrophages, which were previ-
ously polarized to the M1 state by lipopolysaccharides. 
In vivo studies showed a quicker wound healing rate on 
diabetic mice model wounds, proving the efficacy of cur-
cumin-loaded nanofibers in chronic wounds.58
Likewise, in a study in which the hydroxylase inhibi-
tor dimethyloxalylglycine was embedded in PCL, a simi-
lar anti-inflammatory modulation of macrophages was 
demonstrated.61 On RAW264.7 macrophages, Zhang 
et al.61 observed a decreased production of the pro-
inflammatory cytokines (IL-1, IL-6) and an enhancement 
of anti-inflammatory signals (IL-4, TGF-β) and growth 
factors (insulin-like growth factor, heparin-binding epi-
dermal-growth-factor-like growth factor).
Schwinté and colleagues produced electrospun PCL 
containing polysaccharide-atorvastatin nano-reservoirs 
by using complexes with poly-aminocyclodextrin.62 
These membranes were tested on THP-1 stimulated by 
lipopolysaccharides. A pronounced decrease in the pro-
duction of pro-inflammatory cytokines TNF-α and IL-6 
(reductions of 60 and 80%, respectively) was verified for 
these M1-like macrophages. This strategy is very interest-
ing to overcome the exacerbated inflammatory phase that 
occurs in non-healing injuries.
Natural biomaterials, such as avian eggshell membrane 
have been widely used on injured skin, especially in Asian 
countries. In a recent study, processed avian eggshell mem-
brane particles have been found to contain collagen, hyalu-
ronic acid, sulfated glycosaminoglycans, and N-glycans, 
which have anti-inflammatory properties and a high poten-
tial as a biological wound dressing biomaterial for chronic 
wounds.63 After polarization of macrophages to an inflam-
matory state, particles were applied and a reduction of IL-1, 
IL-6, and TNF-α secretion occurred, while production of 
the anti-inflammatory IL-10 increased. Furthermore, the 
expression of important pro-inflammatory response recep-
tors (e.g. toll-like receptor 4) were downregulated.63
Other examples of non-commercial materials are the 
novel alginate dressings with aloe vera, which are able to 
modulate the inflammatory phase, promote angiogenesis, 
and stimulate type I collagen production.64
Biomaterial–macrophage interactions: Main 
drawbacks
When a biomaterial is in contact within the human body, a 
series of events occur. These events include65,66:
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•• Immediate protein adsorption on the biomaterial;
•• Cell infiltration (i.e. neutrophils, monocytes, and 
platelets) and adhesion to the biomaterial surface;
•• Production of chemokines and cytokines by adhered 
cells;
•• Macrophage fusion forming multinucleated foreign 
body giant cells;
•• Interaction between macrophages or foreign body 
giant cells and inflammatory or wound healing cells 
in general.
The formation of foreign body giant cells originates from 
fused variants of M1 macrophages in an attempted phago-
cytic response to eradicate a large foreign body.66–68 As a 
result of this effort, foreign body giant cells secrete reac-
tive oxygen species and matrix metalloproteinases, pro-
voking a failure to deposit extracellular matrix and the 
consequent local persistence of damage-associated molec-
ular patterns and continuous activation of macrophages.69,70 
Since regeneration is not achieved, tissue granulation 
occurs, finally forming a fibrous capsule.71,72 This is a very 
important effect in the cutaneous healing area, especially if 
a wound dressing biomaterial must be left in contact for a 
prolonged period.
This foreign body response also alters the material sur-
face, leading to biomaterial degradation, inducing a con-
tinuous inflammatory response and consequent failure of 
injury repair, which finally has an undesirable impact on 
biocompatibility.71 Hence, the formation of foreign body 
giant cells is the “dark side” of macrophages in interaction 
with biomaterials.
Final remarks
Biomaterial–macrophage interactions are a “hot topic” 
nowadays. A beneficial macrophage response in contact 
with a biomaterial is therefore crucial for a successful 
overcome of the perpetual inflammatory phase that occurs 
in chronic wounds. Thus, biomaterials that induce the 
“M1–M2 shift” are ideal candidates for promoting wound 
closure and avoiding susceptibility to contamination from 
the early stages. Not only a huge effort has been given to 
develop newly synthesized biomaterials with anti-inflam-
matory properties, but also a deeper understanding of the 
selective impact on wound macrophage polarization of 
currently applied biomaterials is being explored. However, 
the field of macrophage immunomodulation and biomate-
rial–macrophage interaction is still “immature”. The pro-
gress that has been made in understanding macrophage 
polarization under physiological versus pathological 
wound conditions has given a boost to research in bioma-
terial science. The focus on immunomodulatory effects 
may lead to the establishment of a novel generation of 
immunomodulating biomaterials, able to influence the 
behavior of the wound healing key players, such as differ-
ent macrophage phenotypes.
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